Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
26 Octubre 2023 - 6:00AM
Business Wire
- Can-Fite signed an agreement with Collaborations
Pharmaceuticals, a leading expert in Artificial Intelligence and
Machine Learning
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncology and inflammatory diseases,
today announced that it entered into an agreement with
Collaborations Pharmaceuticals, Inc. (CPI) to develop anti-cancer
drugs utilizing artificial intelligence (AI) and machine learning
(ML) techniques. This project will aim to develop a next-generation
A3 adenosine receptor drug agonists that significantly reduce the
development time and cost of bringing such drugs to market.
CPI will utilize, apply and use AI and ML tools, including their
MegaSyn generative AI method, to design new molecules with high
affinity and selectivity to the A3AR Can-Fite target. CPI will also
perform the chemical synthesis of the newly designed molecules with
the ultimate goal of developing novel and robust anti-cancer drug
candidates. Can-Fite will perform the testing of the biological
anti-cancer effects and validate the molecular mechanism of the
novel, chemically synthesized drug candidates.
“Our vision is to deliver in silico small molecule drug
candidates in a better and faster way to patients via a
collaboration with Collaborations Pharmaceuticals. Our accumulated
experience of bringing anti-cancer drugs which target the A3AR from
lab to patients will be implemented into this AI drug development
project,” stated Prof. Pnina Fishman, Executive Chairman and CSO at
Can-Fite.
“We are delighted that Can-Fite chose our team of experts for
this AI-led drug discovery collaboration and look forward to
demonstrating what our technology can do,” said Sean Ekins, PhD,
DSc., CEO and Founder of Collaborations Pharmaceuticals, Inc. We
also look forward to complementing their outstanding scientific
approach with our integrated technology platform and ability to
generate novel and selective molecules."
About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
(NYSE American: CANF) (TASE: CANF) is an advanced clinical stage
drug development Company with a platform technology that is
designed to address multi-billion dollar markets in the treatment
of cancer, liver, and inflammatory disease. The Company’s lead drug
candidate, Piclidenoson recently reported topline results in a
Phase III trial for psoriasis and is expected to commence a pivotal
Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being
evaluated in a Phase IIb trial for the treatment of steatotic liver
disease (SLD), a Phase III pivotal trial for hepatocellular
carcinoma (HCC), and the Company is planning a Phase IIa study in
pancreatic cancer. Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug
Administration. Namodenoson has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company’s third drug candidate, has shown
efficacy in the treatment of erectile dysfunction. These drugs have
an excellent safety profile with experience in over 1,600 patients
in clinical studies to date. For more information please visit:
www.can-fite.com.
About Collaborations Pharmaceuticals: Collaborations
Pharmaceuticals, Inc. developed MegaSyn for generative drug design.
In addition they have developed Assay Central® software for data
curation and machine learning as well as curated model collections
such as MegaTox®, MegaTrans® and MegaPredict®. Collaborations
Pharmaceuticals, Inc. performs research and development on
innovative therapeutics for multiple rare and neglected diseases
and consults for pharmaceutical and consumer product companies. For
more information, http://www.collaborationspharma.com/
Forward-Looking Statements This press release may contain
forward-looking statements, about Can-Fite’s expectations, beliefs
or intentions regarding, among other things, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. All statements in this
communication, other than those relating to historical facts, are
“forward looking statements”. Forward-looking statements can be
identified by the use of forward-looking words such as “believe,”
“expect,” “intend,” “plan,” “may,” “should” or “anticipate” or
their negatives or other variations of these words or other
comparable words or by the fact that these statements do not relate
strictly to historical or current matters. Forward-looking
statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to the COVID-19 pandemic and the Russian invasion of
Ukraine; risks related to not satisfying the continued listing
requirements of NYSE American; and statements as to the impact of
the political and security situation in Israel on our business.
More information on these risks, uncertainties and other factors is
included from time to time in the “Risk Factors” section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
30, 2023 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026204622/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114 Collaborations Pharmaceuticals, Inc. Sean Ekins,
PhD., D.Sc. CEO and President
sean@collaborationsPharmaceuticals.com
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De May 2023 a May 2024